Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Ascendis Pharma A/S (ASND)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2016
2017
2018
2019
2020
2021
2022
2023
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | €720.1M | €363.6M | €266.7M | €51.2M | €7.8M | €7.0M | €13.4M | €10.6M | €1.5M | €4.6M | €8.1M |
| Gross profit | €625.2M | €319.4M | €222.3M | €39.0M | €4.3M | €7.0M | €13.4M | — | — | — | — |
| Research & development | €303.6M | €307.0M | €413.5M | €379.6M | €295.9M | €260.9M | €191.6M | €140.3M | €99.6M | €66.0M | €40.5M |
| Operating income | −€136.3M | −€278.8M | −€455.5M | −€561.8M | −€451.8M | −€330.6M | −€226.7M | −€154.8M | −€111.5M | −€72.9M | −€41.8M |
| Net income | −€228.0M | −€378.1M | −€481.4M | −€583.2M | −€383.6M | −€419.0M | −€218.0M | −€130.1M | −€123.9M | −€68.5M | −€32.9M |
| Basic EPSper diluted share | -€3.76 | -€6.53 | -€8.55 | -€10.40 | -€7.00 | -€8.28 | -€4.69 | -€3.17 | -€3.68 | -€2.58 | -€1.39 |
| Diluted EPSper diluted share | -€3.76 | -€6.53 | -€8.55 | -€10.40 | -€7.00 | -€8.28 | -€4.69 | -€3.17 | -€3.68 | -€2.58 | -€1.39 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 2, 2026Form 4 | SMITH SCOTT THOMASEVP & Chief Financial Officer | BuyOrdinary Shares | 100 | $219.00 | $21.9K | 4.4K |
| May 29, 2026Form 4 | BIENAIME JEAN JACQUESDirector | BuyOrdinary Shares | 100 | $223.50 | $22.4K | 900 |
| May 29, 2026Form 4 | BIENAIME JEAN JACQUESDirector | BuyOrdinary Shares | 200 | $222.30 | $44.5K | 800 |
| May 29, 2026Form 4 | BIENAIME JEAN JACQUESDirector | BuyOrdinary Shares | 200 | $223.76 | $44.8K | 600 |
| May 29, 2026Form 4 | SMITH SCOTT THOMASEVP & Chief Financial Officer | BuyOrdinary Shares | 250 | $223.32 | $55.8K | 4.3K |